Lenz & Staehelin has advised investment bank Jefferies as underwriter in the public offering of shares of the Lausanne based ADC Therapeutics, a commercial-stage biotechnology company helping to improve the lives of those affected by cancer and listed on the New York Stock Exchange. There were 12M shares sold at a price of USD 5 […]
Cavotec has successfully carried out a directed share issue, with the guidance and legal assistance of Bär & Karrer. The share placement involved 12,452,830 shares sold at a subscription price of SEK 13.25 per share, resulting
Only one year after the companthiy’s incorporation, Kellerhals Carrard has advised ETH Zurich spin-off EthonAI in its USD 6.8 million oversubscribed seed round. The round was co-led by Earlybird Venture Capital and La Famiglia with
ADC Therapeutics, a commercial-stage biotechnology company headquartered in Lausanne, announced the pricing of an underwritten offering of 12 m ADCT shares currently owned by A.T. Holdings II, an affiliate of Auven Therapeutics Holding, at a
Baker McKenzie advised PSP Swiss Property on the conversion of its CHF 1.8 billion bond portfolio to green bonds based on the company’s Green Bond Framework. The Green Bond Framework is tied to a green
Credit Suisse, acting through its London branch, successfully completed its issuance of EUR 750 m aggregate principal amount of 5.550 per cent. senior notes due 2026. Credit Suisse issued the Notes through its London branch in two separate
ABB E-mobility, a global leader in electric vehicle (EV) charging solutions, has signed an agreement with four minority investors to raise an additional CHF 325 million in funds, in exchange for a total shareholding of approximately 12
Swiss Life Holding successfully placed three tranches of senior bonds totalling CHF 600 million on 11 January 2023, comprising a tranche of CHF 200 million with maturity in 2026 and a 2.04% coupon, a tranche of CHF 200 million with maturity in 2028
Credit Suisse has successfully completed its issuance of GBP 500 m aggregate principal amount of 7.750 per cent. senior notes due 2026. The Notes were issued under Credit Suisse’s Euro Medium Term Note Programme. The Notes have
As we have informed here NLS Pharmaceutics, a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announced that it has
